On February 1, 2023 Veracyte, Inc. (Nasdaq: VCYT) reported that six abstracts highlighting new data focused on the company’s Decipher urologic cancer testing offerings will be presented at the 2023 ASCO (Free ASCO Whitepaper) Genitourinary (GU) Cancers Symposium, taking place in San Francisco, Calif. and online, February 16-18, 2023 (Press release, Veracyte, FEB 1, 2023, View Source [SID1234626718]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Data being presented include new insights derived from Veracyte’s Decipher Genomics Resource for Intelligent Discovery (GRID) database, which suggest potential opportunities to further personalize treatment for men with prostate cancer. Additionally, researchers will present new Decipher Prostate Genomic Classifier clinical utility data from the prospective, phase 3, randomized clinical trial, G-MINOR (Genomics in Michigan ImpactiNg Observation or Radiation).
"Veracyte is committed to helping empower physicians with the insights they need to guide more informed, individualized treatment for patients with urologic cancers," said Elai Davicioni, Ph.D., Veracyte’s medical director for Urology. "The data being presented at this year’s ASCO (Free ASCO Whitepaper) GU Cancers Symposium advance our understanding of how our Decipher genomic tests and Decipher GRID database may help physicians further stratify risk and guide treatment decisions for their patients with prostate or bladder cancer."
Veracyte also expects additional data regarding the Decipher Prostate test to be highlighted in the following general session presentation:
Title:
Treatment Combinations for Patients Starting Androgen-Deprivation Therapy: Building on Recent Victories
Presenter:
Gerhardt Attard, M.D., Ph.D., University College London Cancer Institute
Date/Time:
Thursday, February 16, 10:00 a.m. – 11:30 a.m. PST
Location:
Level 3, Ballroom
Below are details of the abstracts that will be presented as posters at the 2023 ASCO (Free ASCO Whitepaper) GU Cancers Symposium in the Moscone Center in Moscone West, Level 1.
Title:
Use of prostate cancer subtyping by gene expression to predict response to radiation and chemohormonal therapies.
Presenter:
Adam Benjamin Weiner, M.D., UCLA
Date/Time:
February 16, 2023; 11:30 a.m. PST
Abstract #:
241
Poster #:
J6
Title:
Determining the impact of genomic classifier testing on patient-reported quality of life after prostatectomy: Results from the G-MINOR randomized trial.
Presenter:
Udit Singhal, M.D., University of Michigan
Date/Time:
February 16, 2023; 11:30 a.m. PST
Abstract #:
345
Poster #:
M3
Title:
Comparative transcriptomic analysis of DNA-damage response and androgen receptor pathway activity between biopsy and radical prostatectomy specimens before and after pre-operative real-time MRI-guided stereotactic body radiotherapy.
Presenter:
Himanshu Nagar, M.D., Weill Cornell Medicine
Date/Time:
February 16, 2023; 11:30 a.m. PST
Abstract #:
375
Poster #:
N13
Title:
Effect of neoadjuvant stereotactic body radiation therapy (SBRT) on the immune microenvironment of high-risk localized prostate cancer in paired transcriptomic analysis of pretreatment biopsy and irradiated prostatectomy specimens.
Presenter:
Ariel E. Marciscano, M.D., Weill Cornell Medical College
Date/Time:
February 16, 2023; 11:30 a.m. PST
Abstract #:
371
Poster #:
N9
Title:
Distinct gene expression patterns identify patients who relapse after neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 study.
Presenter:
Moritz Reike, M.D., University of British Columbia
Date/Time:
February 17, 2023; 12:30 p.m. PST
Abstract #:
549
Poster #:
M12
Title:
Genomic analysis from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with MIBC undergoing cystectomy.
Presenter:
Shilpa Gupta, M.D., Cleveland Clinic Taussig Cancer Center
Date/Time:
February 17, 2023; 12:30 p.m. PST
Abstract #:
559
Poster #:
N2